Joshua Fitch, Senior Editor

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

With this expanded FDA clearance, the wearable becomes the first FDA-cleared, non-drug therapy to treat acute migraines in children.

The application indication is for adults and pediatric patients aged 12 years and older with CSU whose disease is not adequately controlled with H1 antihistamines.

H. Westley Phillips, MD, joined us to provide clinical pearls regarding the early identification of drug-resistant epilepsy patients in the primary care setting.

With the decision, Kebilidi becomes the first FDA-approved gene therapy for AADC deficiency, and is indicated for adult and pediatric patients.

A discussion of tips and recommendations general providers can use when evaluating ADHD in pediatric patients.

A target action date for potential approval of prademagene zamikeracel (pz-cel) has been set for April 29, 2025.

The primary endpoint of the study was survival free of BPD at 36 weeks' postmenstrual age.

A key update includes providing CPR with rescue breaths and chest compressions to all persons in cardiac arrest after water removal.

Data stems from the first 4 patients dosed in a low-dose cohort of an ongoing phase 1/2 open-label trial.

The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025.

In this video discussion, David Turkewitz, MD, offers clinical pearls to reduce the risk of SIDS and reviews the updated 2022 guidelines from the AAP.

At any point in the study, adolescents who used cannabis reported a greater number of psychosis spectrum symptoms.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

Rakesh Jain, MD, MPH, notes that with increasing ADHD trends, a newly-available and FDA-approved non-stimulant tool can help treat more patients.

The study outcomes were estimated IMD cases and deaths averted by MenACWY vaccination in adolescents and adults aged 11 to 23 years.

The federal agency has not raised any concerns regarding safety and efficacy of tapinarof cream, 1%.

Severe outcomes among children with pneumonia were uncommon, regardless of whether antibiotics were received based on study results.

Application acceptance was based on positive results with monthly and bi-monthly dosing data from a phase 3 trial.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from last week, all in one place.

Jain breaks down key benefits of clonidine hydrochloride (ONYDA XR; Tris Pharma) to treat ADHD among patients aged 6 years and older.

These tips can help your patients have a fun, exciting, and thrilling Halloween, all while staying safe.

The detected reduction in HRs for suicidal ideation among adolescents with obesity prescribed GLP1R suggests potential avenues for future research.

The product was sent to distributors by direct delivery in 35 states and Amazon.com.

The approval makes methotrexate, currently, the only only oral liquid methotrexate on the market approved for both adult and pediatric indications.

The fibrin sealant solution is now available in 18 countries.

"The novel RSV prevention strategies may reduce ICU morbidity and mortality for children," the study authors concluded.

Look back at several quick video interviews discussing the expanding role of artificial intelligence, how RSV treatment has evolved, and much more.

As the authors emphasized, “Expansion of these services will be essential to meet the needs of patients experiencing food allergy-related anxiety."

In all, 51.9% of patients entered with or achieved complete disease clearance at least once during the 48-week study.